TScan Therapeutics Inc (TCRX): Upcoming Poster Presentations include 2...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	30
Posts	4278
Boards Moderated	0
Alias Born	03/20/2011

FACT-MASTER

Re: jondoeuk post# 229

Tuesday, 04/23/2024 4:54:00 PM

Tuesday, April 23, 2024 4:54:00 PM

Upcoming Poster Presentations include 2 Non-Clinical Presentations:

Question: Does this mean that they these therapies do not need FDA approval ?

Title: Nonclinical Development of T-Plex Component TSC-204-A0101: A Natural TCR-T Cell Therapy for the Treatment of MAGE-A1- and HLA-A*01:01-Positive Cancers
Presenter: Shazad Khokhar, Ph.D.
Abstract Number: 834
Session Title: Wednesday Posters: Immune Targeting and Approaches with Genetically-Modified Cells and Cell Therapies
Session Date/Time: Wednesday, May 8; 12:00 p.m. Eastern Time
Location: Exhibit Hall

Title: Non-Clinical Development of T-Plex Component TSC-201-B0702: A TCR-T Cell Therapy Directed to a Novel HLA-B*07:02 Restricted MAGE-C2 Epitope for the Treatment of Solid Tumors
Presenter: Hannah Bader, Ph.D.
Abstract Number: 835
Session Title: Wednesday Posters: Immune Targeting and Approaches with Genetically-Modified Cells and Cell Therapies
Session Date/Time: Wednesday, May 8; 12:00 p.m. Eastern Time
Location: Exhibit Hall